Tenaya Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
TNYA$0.39+9.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(In thousands, except share data)
| Common Stock · AdditionalPaid-In · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Loss · Deficit · Equity | ||||||||
| Balance as of January 1, 2025 | 86,542,340 | $8 | $607,229 | $28 | $(514,411) | $92,854 | ||
| Issuance of common stock and warrants in follow-on offering, net of issuance costs of $3,699 | 75,000,000 | 8 | 48,793 | — | — | 48,801 | ||
| Issuance of common stock upon vesting of restricted stock units | 295,191 | — | — | — | — | — | ||
| Issuance of common stock in connection with at-the market sales, net of issuance costs of $280 | 822,566 | — | 912 | — | — | 912 | ||
| Stock-based compensation | — | — | 3,731 | — | — | 3,731 | ||
| Other comprehensive loss | — | — | — | (38) | — | (38) | ||
| Net loss | — | — | — | (26,864) | (26,864) | |||
| Balance as of March 31, 2025 | 162,660,097 | $16 | $660,665 | $(10) | $(541,275) | $119,396 | ||
| Common Stock · AdditionalPaid-In · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Loss · Deficit · Equity | |||||||
| Balance as of January 1, 2024 | 68,330,342 | $7 | $542,805 | $(106) | $(403,282) | $139,424 | |
| Issuance of common stock and pre-funded warrants, net of issuance costs of $3,236 | 8,888,890 | 1 | 46,761 | 46,762 | |||
| Issuance of common stock upon exercise of stock options and vesting of restricted stock units | 246,708 | — | 11 | — | — | 11 | |
| Issuance of common stock upon exercise of pre-funded warrants | 1,051,594 | — | 1 | — | — | 1 | |
| Stock-based compensation | — | — | 4,224 | — | — | 4,224 | |
| Other comprehensive income | — | — | — | (14) | — | (14) | |
| Net loss | — | — | — | — | (32,228) | (32,228) | |
| Balance as of March 31, 2024 | 78,517,534 | $8 | $593,802 | $(120) | $(435,510) | $158,180 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.